By the way, at any other time in history this would have C Level Contact List been impossible. But the crucial question is: who will have access to the vaccine C Level Contact List and who will benefit from it? In recent months, all large countries with economic capacity have secured the rights to use vaccines or are promoting research with state companies or state participation. The C Level Contact List entry of the German state into the Tübingen-based company CureVac is certainly no exception.
The fact that CureVac is now going public on the US Stock C Level Contact List Exchange also shows the transnational interconnectedness in this area. The United States also has agreements with the German company BioNTech, but also with Johnson & Johnson, Sanofi and C Level Contact List several others. Australia, Canada, Japan and many other countries have signed similar contracts. There are also numerous efforts in this direction: in Europe, for example, an alliance of Germany, France, Italy C Level Contact List and the Netherlands has agreed with the British group AstraZeneca to supply 400 million doses.
The European Union wants to participate in the COVAX C Level Contact List initiative, created by the WHO together with the global alliance for vaccines GAVI, which aims to make a collective purchase of 2,000 million doses by 2021 and distribute them equitably C Level Contact List throughout the world. Does it make sense for European states to declare themselves in favor of universal availability of the vaccine? After all, countries like Germany and France will first vaccinate their C Level Contact List own inhabitants before countries in the global South are taken into account. If the basic philosophy of this global pandemic is: "No one is safe until everyone is safe", then it is important to popularize this idea when distributing the vaccine. On the other hand, it is clear that the task of each government is to take care of its own people in the first place.